IngredientsProcyanidins are proanthocyanidins built from the flavan-3-ol monomers (+)-catechin and (−)-epicatechin. They belong to the broader class of condensed tannins and represent a subgroup within the proanthocyanidin family. Proanthocyanidins, including the lesser bioactive and bioavailable polymers (four or more catechins), represent a group of condensed flavan-3-ols, such as procyanidins, prodelphinidins, and propelargonidins.
Procyanidins are polyphenols abundant in dietary fruits, vegetables, nuts, legumes, and grains with a variety of chemopreventive biological effects. The full chemical class name is "procyanidin-type proanthocyanidins," and they are also collectively referred to as oligomeric proanthocyanidins (OPCs) or, in older literature, procyanidolic oligomers (PCOs). Collectively, mixtures of proanthocyanidin dimers, trimers, tetramers, and larger molecules are referred to as procyanidolic oligomers (PCOs) or oligomeric proanthocyanidins (OPCs). Although PCOs exist in many plants as well as red wine, commercially available sources of PCOs include extracts from grape seed skin (Vitis vinifera) and the bark of the maritime (Landes) pine.
Flavan-3-ols include two phenolic rings A and B and a heterocyclic ring C. The general chemical structure of a polymeric proanthocyanidin consists of linear chains of 5,7,3′,4′-tetrahydroxy or 5,7,3′,5′-pentahydroxy flavonoid 3-ol units linked together through common C(4)-(6) and/or C(4)-C(8) bonds. The monomer unit (generally termed "leucoanthocyanidin") of the polymer chain may be based on either of two stereochemistries of the C-ring, at positions 2 and/or 4 designated cis (called epicatechins) or trans (called catechin).
Two principal structural subtypes are distinguished by the nature of the inter-flavan bond. Unlike B- and C-type procyanidins, which feature a single C-C interflavan linkage allowing rotational flexibility, A-type procyanidins A1 and A2 possess an additional ether (C-O-C) bond alongside the C-C bond, severely restricting conformational freedom and resulting in a single dominant conformation in the ground state. This structural difference has important consequences for both bioavailability and biological activity.
Procyanidins are classified by their degree of polymerization (DP): monomers (catechin and epicatechin), dimers (e.g., procyanidins B1 and B2), trimers (e.g., procyanidin C1), and larger oligomers and polymers. Oligomeric proanthocyanidins (OPC) strictly refer to dimer and trimer polymerizations of catechins. There are 14 dimeric, 11 trimeric procyanidins, and 1 tetrameric procyanidin that have been identified from grape seeds.
Although procyanidin levels within plants and foods remain unclear, the application of nuclear magnetic resonance (NMR) and mass spectrometry (MS) has enabled the structure elucidation in these phenolic compounds. To date, the structures of monomeric units catechin and epicatechin as well as some of their lower-order oligomers have been established, but the identification of polymeric procyanidins and the extent of their formation in many plants and foods remains limited.
Procyanidins can be found in many plants, most notably apples, maritime pine bark, cinnamon, aronia fruit, cocoa beans, grape seed, grape skin, and red wines of Vitis vinifera (the common grape). However, bilberry, cranberry, black currant, green tea, black tea, and other plants also contain these flavonoids.
Procyanidins are dense in grape seeds and skin, and therefore in red wine and grape seed extract, cocoa, nuts and all Prunus fruits (most concentrated in the skin), and in the bark of Cinnamomum (cinnamon) and Pinus pinaster (pine bark; formerly known as Pinus maritima), along with many other pine species.
Procyanidins can also be isolated from Quercus petraea and Q. robur heartwood (wine barrel oaks). Açaí oil, obtained from the fruit of the açaí palm (Euterpe oleracea), is rich in numerous procyanidin oligomers. Apples contain on average per serving about eight times the amount of procyanidin found in wine, with some of the highest amounts found in the Red Delicious and Granny Smith varieties.
Within grape seeds specifically, major flavan-3-ol monomers in grape comprise (+)-catechin, (−)-epicatechin, and (−)-epicatechin 3-gallate, (−)-epigallocatechin, and trace amounts of (+)-gallocatechin. Dimers, trimers, tetramers, pentamers, hexamers, heptamers, and their gallates have been documented in grape seeds.
Human consumption of pine bark dates back thousands of years, and the first commercial pine bark extract was patented in 1948 by Dr. Jacques Masquelier from France. Botanical extracts from pine bark have a long-standing history of use in traditional medicine, e.g., for wound healing.
A historically significant episode in the popularization of pine bark involves 16th-century exploration. Professor Masquelier got his inspiration from reading about Jacques Cartier's 1535 expedition up the St. Lawrence River. Cartier's crew were trapped in the ice and dying of scurvy. The crew survived after native Iroquois gave them spruce beer brewed from the bark and needles of pines growing by the river. Prof. Masquelier speculated pine extracts in the brew contained Vitamin C and flavonoids that helped the crew's recovery.
In traditional Chinese medicine, hawthorn berries — a procyanidin-rich plant — were employed historically to promote digestion and heart function. The use of grape seeds and bark in various folk remedy traditions reflected longstanding empirical observations about their beneficial effects on circulation and inflammation, though these uses predate any knowledge of procyanidins as specific chemical entities.
Study of the bioactive components of grape seed extracts was first initiated at the beginning of the 20th century. Albert Szent-Györgyi, a 1937 Nobel Prize winner, discovered flavonoids while working on the segregation of vitamin C, terming them "vitamin P".
Subsequently, Professor Jacques Masquelier postulated that because pine bark exhibited ascorbate-like effects, it must contain vitamin C along with flavonoids, which he designated as "pycnogenols" — a term no longer used by the scientific community except as a trademark for proanthocyanidins extracted from French maritime pine bark. Masquelier improved and patented a technique to extract oligomeric grape seed proanthocyanidins in 1947, and observed that the bioflavonoids derived from grape seeds appeared to be superior in both concentration and antioxidant effect to those from pine bark.
During the 1960s, the world's first pine bark extract was launched in France as a herbal remedy under the name Flavan®. In 1965, Masquelier proposed an impressive number of vascular benefits of the Maritime Pine bark extract (Flavan®) made according to his extraction method.
Procyanidins are available commercially primarily as standardized extracts from two dominant raw material sources: grape seed (Vitis vinifera) and French maritime pine bark (Pinus pinaster). The most extensively researched pine bark extract is Pycnogenol®. Pycnogenol® was found to contain mainly procyanidins, their monomers catechin and epicatechin, taxifolin, as well as phenolic acids. The total amount of procyanidins in Pycnogenol® is standardized to 70 ± 5% and thus meets the specifications for maritime pine extract described in the United States Pharmacopeia (USP).
Most research on French maritime pine extract has used Pycnogenol, as opposed to the other standardized extracts, Oligopin and Flavangenol. These extracts have slightly different chemical compositions, due to different extraction techniques, and there currently isn't enough evidence to know whether Oligopin and Flavangenol work the same as Pycnogenol.
Grape seeds contain about 5–8% polyphenols (depending on the variety), including the flavan-3-ol monomers catechin, epicatechin, gallocatechin, epigallocatechin, and epicatechin 3-O-gallate, as well as procyanidin dimers, trimers, and highly polymerized procyanidins.
Procyanidin content in dietary supplements has not been well documented. Pycnogenol is a dietary supplement derived from extracts from maritime pine bark that contains 70% procyanidins.
As with pine bark extract, grape seed extract also contains oligomeric proanthocyanidins (OPCs); confusion has arisen when grape seed extract was marketed as containing "Pycnogenol," the proprietary name used for OPCs specifically derived from pine bark.
Cranberry (Vaccinium macrocarpon) is a commercially important source of A-type procyanidins (PACs), which are featured prominently in cranberry dietary supplements targeted at urinary tract health. The application of procyanidins, extracted from the pulp and skin of many dark-colored berry fruits, especially red grapes, cocoa, and their seeds, in food, biochemistry, cosmetics, and textile fields, has also been researched in recent years.
The antioxidant activity of proanthocyanidin is superior to that of vitamins C and E, β-carotene, or monomeric flavanol, including (+)-catechin. Furthermore, grape seed extracts containing 39–73% proanthocyanidin have also been shown to have strong antioxidant potency. The multi-ring polyphenolic structure enables efficient electron donation and free radical scavenging across a broad spectrum of reactive oxygen species.
One of the most mechanistically well-characterized actions of procyanidins involves the vascular endothelium. The vasorelaxant properties of procyanidins result from their ability to stimulate the rapid formation of nitric oxide (NO) through endothelial nitric oxide synthases (eNOS), leading in turn to increased accumulation of cyclic guanosine monophosphate (cGMP).
Procyanidin C1 induces a potent vasorelaxant effect on phenylephrine-constricted endothelium-intact thoracic aortic rings but had no effect on denuded thoracic aortic rings. Moreover, procyanidin C1 caused a significant increase in nitric oxide (NO) production in endothelial cells.
In addition to NO stimulation, the improvement in cardiovascular function with products containing high amounts of procyanidins is consistent with studies on isolated vessels showing that purified procyanidins cause endothelium-dependent vasodilatation via NO release and inhibit the synthesis of endothelin-1. Endothelin-1 is a potent vasoconstrictor peptide, and its inhibition contributes to vascular tone reduction.
Procyanidin-mediated anti-inflammatory molecular mechanisms include, among others, the modulation of the arachidonic acid pathway, the inhibition of the gene transcription, protein expression, and enzymatic activity of eicosanoid generating enzymes, the production and secretion of inflammatory mediators (such as cytokines and nitric oxide), the inhibition of mitogen-activated protein kinase (MAPK) pathway activation, and the modulation of the nuclear factor-κB (NF-κB) pathway.
Cell studies with wild grape procyanidins have elaborated these pathways in detail: these procyanidins significantly reduced NO, PGE₂, and ROS production and also inhibited the expression of proinflammatory mediators such as iNOS and COX-2 protein expressions. They also significantly reduced LPS-stimulated expression of proinflammatory cytokines such as TNF-α and IL-1β, prevented nuclear translocation of NF-κB p65 subunit by reducing IκBα and NF-κB phosphorylation, and inhibited LPS-induced phosphorylation of p38 MAPK.
Grape seed extracts have dual anticoagulant/antiplatelet activity due to the high polyphenolic content. Grape seed extract (GSE) modulates the coagulation process in human plasma. Grape seed extract's action on human plasma resulted in prolongation of blood plasma clotting time (APTT, PT, TT), and a reduction of thrombin-induced plasma polymerization.
Several studies have revealed that polyphenols may delay carbohydrate digestion and absorption by inhibiting α-glucosidase and α-amylase, consequently reducing postprandial hyperglycemia which may prevent development of diabetes mellitus. This enzymatic inhibition is one proposed mechanism by which procyanidin-rich extracts may influence glycemic parameters.
A critical and frequently underappreciated aspect of procyanidin biology is their limited direct bioavailability. Studies indicate that PACs, due to their large molecular size and complexity, have limited oral bioavailability. However, small amounts that are absorbed through the gastrointestinal tract can still exert systemic effects.
Procyanidins are metabolized by gut microbiota into low-molecular-weight metabolites, such as valerolactones and phenolic acids, which exhibit anti-adhesion bioactivity in urine and contribute to their effectiveness against urinary tract infections. It has been shown in vivo and in vitro that phenolic acid metabolites may have higher bioavailability than the PACs from which they are derived.
The absorption of dietary polyphenols from the intestine into systemic blood circulation is generally considered to be low and it might be affected by other food components such as dietary fiber, lipids, proteins, digestible carbohydrates, or divalent minerals.
After ingestion of Pycnogenol®, taxifolin, catechin, caffeic acid, ferulic acid, and metabolite 1 [δ-(3,4-dihydroxy-phenyl)-γ-valerolactone] have been detected in the blood plasma of volunteers.
Among the best-supported clinical indications for procyanidin-rich extracts is blood pressure reduction. The efficacy of a standardized grape seed procyanidins extract (GSPE, Enovita) to decrease blood pressure when associated with nondrug intervention (diet and lifestyle modifications) was investigated in a controlled registry study involving 119 healthy, pre- and mildly hypertensive subjects. Two dosages of Enovita were evaluated (150 and 300 mg/day), using blood pressure and heart rate as the primary endpoints and complementing these observations with a laser Doppler flowmetry investigation of the microcirculation state and an evaluation of the plasma oxidative status. After four months of treatment, a statistically significant, higher, and dose-dependent improvement in all endpoints was observed in the treatment groups compared to control, with blood pressure normalizing in 93% of the higher-dosage (300 mg) treatment group.
A separate randomized, double-blind, placebo-controlled study further examined vascular outcomes: this study aimed to investigate the effects of grape seed proanthocyanidin extract (GSPE) on blood pressure and vascular endothelial function in middle-aged Japanese adults with prehypertension. Researchers conducted the study on 6 men and 24 women aged 40–64 years old. Participants were randomized to receive tablets containing either low-dose (200 mg/day) or high-dose (400 mg/day) GSPE, or placebo, for 12 weeks. Systolic and diastolic blood pressures (SBP and DBP, respectively), brachial flow-mediated dilation (FMD), and other cardiovascular parameters were measured before and after 4, 8, and 12 weeks of treatment. The mean SBP in the high-dose group significantly decreased by 13 mmHg after 12 weeks (P = 0.028), although FMD did not change.
A meta-analysis including 15 trials found that pooling the data indicated that grape seed extract may significantly decrease concentrations of fasting plasma glucose, total cholesterol, LDL cholesterol, triglycerides, and C-reactive protein (CRP). The included studies used doses from 100 mg of a grape seed proanthocyanidin extract up to 2,000 mg per day, and study duration ranged from four to 25 weeks.
A human clinical trial was conducted on hypercholesterolemic subjects; GSPE supplementation significantly reduced oxidized LDL, a biomarker of cardiovascular risk.
Evidence strength: Collectively, the data for blood pressure and lipid outcomes is among the strongest for procyanidins in human trials, though most individual trials are small and of relatively short duration. The meta-analytic evidence for blood pressure and lipid effects should be interpreted with caution given heterogeneity in extract composition and dosing across studies. Randomized trials in human beings have yielded conflicting results for some cardiovascular endpoints.
In 39 randomized double-blind, placebo-controlled (RDP) human clinical trials including 2,009 subjects, Pycnogenol® French maritime pine bark extract supplementation for two weeks to six months has been shown to beneficially affect cardiovascular health, chronic venous insufficiency, cognition, joint health, skin health, eye health, women's health, respiratory health and allergies, oral health, and sports performance.
Pycnogenol may reduce symptoms of chronic venous insufficiency and osteoarthritis thanks to its antioxidant, anti-inflammatory, and vasoactive properties; however, the evidence is relatively weak. Many of the trials for CVI are small, funded by the extract manufacturer, and lack robust independent replication.
A small clinical study with 20 healthy volunteers demonstrated that Pycnogenol® intake for four weeks increased gene expression of hyaluronic acid synthase by 44%. In addition, the study revealed a noticeable increase in gene expression involved in collagen de novo synthesis.
A larger skin study examined photoprotective effects: the study found that Pycnogenol® prevented decreases in skin hydration and improved skin elasticity in participants working outdoors for 12 weeks.
Evidence strength: Skin data are largely from small, short-duration trials, many industry-sponsored. Effects on hydration and elasticity are promising but require larger, independent replication before firm conclusions can be drawn.
In a single-center, double-blind, randomized, placebo-controlled study, the effects of oral Pycnogenol® intake (3 × 50 mg/day for a total of 6 months) on hair density, scalp microcirculation, and a variety of skin physiological parameters were studied in Han Chinese menopausal women (N = 76) in Shanghai, China. Pycnogenol® intake significantly increased hair density by 30% and 23% after 2 and 6 months of treatment, respectively, as detected by Trichoscan® evaluation of digital photographs.
Evidence strength: Preliminary; a single trial in a specific demographic (menopausal Han Chinese women). Results cannot be generalized without replication in diverse populations.
Procyanidins have been investigated for neuroprotective and cognitive-enhancing properties. Procyanidins have antioxidative properties that may protect against age-related brain oxidative stress. Previous studies indicated that procyanidin-rich foods could improve cognitive function and prevent neurodegenerative diseases.
A clinical trial specifically examined cognition in older adults: a study hypothesized that grape seed procyanidins extract (GSPE) would have a favorable effect on cognitive function in elderly people with mild cognitive impairment (MCI). A community-based, randomized, double-blind, placebo-controlled trial was conducted. Participants aged 60 years or older with MCI were randomly assigned into the GSPE group (n = 35, 320 mg/day) or placebo group (n = 36) and received capsules for 6 months. Cognitive function was assessed using the Montreal Cognitive Assessment Scale (MoCA).
Results from that trial and related work show mixed findings. After taking Concord grape juice for 16 weeks, there was no significant improvement in learning and retention performance between the intervention group (n = 10, 355–551 mg/day) and the placebo group (n = 11). However, a cocoa drink intervention for 8 weeks improved cognition in subjects with MCI, and showed better performance on Trail Making Test A and B in high (n = 30, 746 mg/day) and intermediate dose treatment groups (n = 30, 390 mg/day) when compared with low-dose group (n = 30, 33 mg/day).
Evidence strength: Preliminary and mixed. Trials differ substantially in procyanidin source, dose, population, and outcome measures. No firm conclusions can be drawn from current human evidence.
The role of procyanidins — specifically A-type PACs from cranberry — in preventing urinary tract infections (UTIs) is one of the most clinically investigated procyanidin applications. Cranberry PACs exhibit a unique mechanism by inhibiting the adhesion of P-fimbriated Escherichia coli to uroepithelial cells, thereby reducing bacterial colonization.
Cranberry metabolites, particularly A-type PACs, flavonoids, and phenolic acids, inhibit Escherichia coli adhesion to urothelial cells, reducing UTI recurrence. Gut microbiota-driven transformation of PACs into bioactive metabolites enhances their efficacy, while cranberry oligosaccharides disrupt biofilm formation in high-risk populations.
A meta-analysis quantified the magnitude of the effect: a meta-analysis investigated whether the content of the main component, proanthocyanidins (PACs), in cranberries affects their ability to prevent UTIs, averaging daily PAC intake already reported in previous RCTs investigating the effectiveness of cranberry in preventing UTIs. Random-effect or fixed-effect models were chosen for statistical analysis based on the heterogeneity. Ten RCTs matching the requirements were included. The results showed that when the daily intake of PACs was at least 36 mg, the risk of UTIs was reduced by 18% (RR = 0.82, 95% CI = 0.69–0.98, p = 0.03).
There is still conflicting scientific data about the usefulness of cranberry products in preventing UTIs. A key complicating factor is bioavailability: the A-type proanthocyanidins are the presumed bioactives in cranberries; however, these compounds have extremely low bioavailability in the human body. Further research has shown that a significant amount of phenolic metabolites produced by microbial breakdown of PACs in the gut can be absorbed by the body and excreted through urine. These phenolic metabolites may inhibit bacterial adhesion to uroepithelial cells at the initial stages, thereby playing a role in preventing bacterial colonization and the progression of UTIs. High doses of PACs intake may enhance anti-adhesion functions in the urinary tract by increasing the production and absorption of phenolic metabolites, thereby reducing the risk of UTIs.
Due to the rigidity of the A-type interflavan bond, A-type PACs may result in less absorbable metabolites in comparison to B-type PACs.
Evidence strength: Moderate. A 2024 meta-analysis of 10 RCTs shows a statistically significant (18%) reduction in UTI risk at ≥36 mg/day PAC dose. The overall evidence base is still considered conflicting, with important caveats around bioavailability, product standardization, and the duration of use required for effect.
Obesity is a chronic metabolic disease resulting from excessive fat accumulation, and recent studies have shown that grape seed proanthocyanidin extract (GSPE) has an antiobesity effect. Research systematically reviews the progress and potential mechanisms of GSPE emphasizing obesity prevention and treatment. However, whether GSPE can reduce body weight is still controversial.
Proanthocyanidins are known to possess antioxidant, antimicrobial, anti-inflammatory, antiallergic, anti-obesity, and vasodilatory properties. Epidemiological evidence has linked the consumption of proanthocyanidins to a reduced risk of chronic diseases, including certain types of cancer and cardiovascular disease, as well as NAFLD.
Evidence strength: Much of the metabolic data derives from animal models (rodents) and in vitro studies. Human RCT evidence specifically for obesity or glycemic outcomes attributable to procyanidins remains limited and inconsistent, with the meta-analytic data on lipid and glucose markers providing the most reliable human signal.
Pycnogenol® intake in osteoarthritis patients reduced gene expression of key catabolic and inflammation markers like MMP-3, MMP-13, and IL-1β by more than 50% within knee cartilage. This comprehensively explains how Pycnogenol® contributes to restoring health in damaged joints. Human trials in osteoarthritis patients suggest symptom reduction, though most are small and of short duration. Pine bark extract demonstrates antioxidant and anti-inflammatory actions and has been studied for a wide range of clinical conditions, including asthma, attention-deficit/hyperactivity disorder (ADHD), chronic venous insufficiency, cardiovascular conditions, diabetes, and erectile dysfunction. However, many clinical trials are methodologically weak, making it difficult to support the use of pine bark extract for any condition.
Procyanidins are available in several forms: standardized capsules, tablets, and loose powders. Pycnogenol is available as capsules or loose powder and is usually given at a dosage of 100 to 200 mg daily, split into two or three doses (e.g., 100 mg twice daily, 50 mg three times daily).
In clinical trials, Pycnogenol dosages ranged from 20 to 360 mg (or were weight based), with the most common duration of use being 2 to 3 weeks; however, longer-term use has been described, including 1 mg/kg/day for ADHD. Daily oral doses of 30–360 mg have been investigated in clinical studies.
For grape seed procyanidin extract specifically, the following dosages have been documented in human studies:
For cranberry-derived PACs targeting UTI prevention, a daily intake of at least 36 mg PACs was the threshold associated with a statistically significant 18% reduction in UTI risk in the meta-analysis.
Proanthocyanidins at 50–100 mg per day is considered a reasonable supplemental level by some clinicians, but optimal levels remain unknown.
While grape seed extract is characterized by a plethora of health-related benefits and is greatly tolerated in modest amounts, there is a possibility that it is hazardous in individuals with bleeding disorders, those undergoing surgery, or in those taking anticoagulant medications such as aspirin and warfarin. Clinical trials have generally reported that grape seed extract is well tolerated.
Common mild adverse effects reported include: stomach upset, nausea, or digestive discomfort, which typically occur with higher doses or empty stomach consumption. Rare but possible allergic responses include skin rashes, itching, or breathing difficulties.
Grape seed extracts have dual anticoagulant/antiplatelet activity due to the high polyphenolic content. Herbs with anticoagulant/antiplatelet properties may enhance the adverse/toxic effect of agents with antiplatelet properties. Bleeding may occur.
OPCs in grape seed extract may interact with anticoagulants (blood thinners); grape seed extract may act as a blood thinner, and could increase the risk of bleeding if taken with other blood thinners such as warfarin (Coumadin), clopidogrel (Plavix), or aspirin.
Cranberry-derived procyanidins carry a specific interaction note: cranberry products are generally safe; however, potential drug interactions, particularly with warfarin, should be considered.
GSPE can negatively interact with a number of medications that are metabolized in the liver, specifically by CYP4503A4 substrates. Other drug interactions include cancer medication regimens, blood pressure medications such as propranolol, and NSAIDs such as ibuprofen and naproxen.
CYP-450 enzyme-mediated herbal drug interactions are possible; caution should be exercised. Grape seed may increase the serum concentration of dextromethorphan.
Due to their antiplatelet properties, procyanidin-rich supplements are generally flagged as a concern in the perioperative period. The dual anticoagulant/antiplatelet mechanisms documented in vitro and ex vivo studies suggest that discontinuation before surgery is prudent, though specific clinical guidance is not yet established in formal guidelines.
Information regarding safety and efficacy in pregnancy and lactation is lacking.
Grape seed is contraindicated in individuals with known hypersensitivity.
Previous studies reported that GSPE exerts anti-inflammatory, anti-carcinogenic, anti-mutagenic, and anti-ischemia/reperfusion injury effects, as well as cardioprotective and neuroprotective benefits.
The documented or investigated health areas span multiple organ systems:
Pycnogenol® French maritime pine bark extract showed antioxidative effects, anti-inflammatory abilities, beneficial effects on endothelial function, and reinforcing effects on the extracellular matrix.
The overall evidence base for procyanidins is heterogeneous. The mechanistic science (in vitro, ex vivo, and animal model data) is extensive and internally consistent in demonstrating antioxidant, anti-inflammatory, and vasoactive properties. Human clinical evidence is substantially more limited. The areas with the strongest human evidence are blood pressure (multiple small RCTs and one registry study) and UTI prevention (meta-analysis of 10 RCTs). For most other indications, available human trials are small, frequently industry-sponsored, and of short duration, precluding definitive conclusions. The structure-activity relationships of procyanidins, especially the relationship between degrees of polymerization and their antioxidant, anticancer, antidiabetic, anti-obesity, and cardioprotective effects as well as their potential mechanisms, remain an active area of research.
Health conditions that Procyanidin may help support.
Procyanidins (dimeric and oligomeric proanthocyanidins from grape seed, pine bark, cocoa) improve endothelial NO production, inhibit ACE, reduce LDL oxidation, and lower blood pressure. RCTs with procyanidin-rich extracts confirm reductions in SBP of ~6 mmHg. They are the primary bioactive in grape seed extract and Pycnogenol studied for arterial health.
Procyanidin oligomers (from apple polyphenol extract and grape seed) selectively and intensively promote proliferation of hair epithelial cells in vitro and activate hair follicle growth in vivo. Topical apple procyanidin B-2 in clinical trials produced significant increases in hair count in men with androgenetic alopecia.
Procyanidins (oligomeric proanthocyanidins from grape seed and pine bark) are oral and topical agents used to prevent postprocedural hyperpigmentation. They inhibit tyrosinase, scavenge ROS, and have been cited among oral depigmenting agents in dermatological reviews.
Topical procyanidin B2 (from apple and grape polyphenol extract) promotes hair follicle cell proliferation via Wnt/β-catenin signaling and VEGF upregulation. Multiple Japanese RCTs (Takahashi 1998, Kamimura 2000/2002) demonstrated significant increases in terminal hair count versus placebo at 6 months. Topical procyanidin 0.7% was included in the 2025 network meta-analysis of male AGA trials as one of nine active comparators.
Procyanidins are a subclass of proanthocyanidins (B-type catechin/epicatechin dimers and oligomers) present in Pycnogenol, grape seed, and other plant extracts studied for CVI and varicose veins. Pycnogenol is standardized to 70% procyanidins and has been shown in multiple RCTs to reduce CVI edema, improve venous tone in varicose vein segments, and slow varicose vein progression. Their mechanism includes collagen stabilization, anti-inflammatory effects, and reduction of capillary permeability.
Body systems that Procyanidin may help support.
Go back